Search

Your search keyword '"Floßmann, Oliver"' showing total 231 results

Search Constraints

Start Over You searched for: Author "Floßmann, Oliver" Remove constraint Author: "Floßmann, Oliver"
231 results on '"Floßmann, Oliver"'

Search Results

1. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

2. Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study

3. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

4. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

5. Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring

6. Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage.

7. Long-term outcome of kidney function in patients with ANCA-associated vasculitis.

8. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

9. Determining outcomes and prognostic factors in ANCA associated vasculitis as a platform for the evaluation of newer treatments

11. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

13. Characteristics and outcome of ANCA-associated vasculitides induced by anti-thyroid drugs: a multicentre retrospective case-control study

14. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

15. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature

16. Characteristics and outcome of ANCA-associated vasculitides induced by anti-thyroid drugs: a multicenter retrospective case-control study

19. Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis.

20. Clinical Characteristics and Outcome of ANCA-Associated Vasculitides Induced by Anti-Thyroid Drugs: A Multicenter Retrospective Cohort Study

21. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT

22. Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study

24. COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry

26. COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry

27. Case of the month from the Department of Urology, Oxford University Hospitals, Oxford, UK: open partial nephrectomy of a transplant kidney in a patient with Fabry’s disease

35. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis

36. Explaining fatigue in ANCA-associated vasculitis

39. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up

42. Long-term patient survival in ANCA-associated vasculitis

43. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines

44. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis

45. Long-term survival of ANCA-associated vasculitis: K11

47. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status

48. Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Catalog

Books, media, physical & digital resources